share_log

HC Wainwright & Co. Initiates Coverage On Eliem Therapeutics With Buy Rating, Announces Price Target of $6

HC Wainwright & Co. Initiates Coverage On Eliem Therapeutics With Buy Rating, Announces Price Target of $6

HC Wainwright & Co.以買入評級啓動對Eliem Therapeutics的報道,宣佈目標股價爲6美元
Benzinga Real-time News ·  2022/10/28 06:28

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Eliem Therapeutics (NASDAQ:ELYM) with a Buy rating and announces Price Target of $6.

HC Wainwright & Co. 分析師道格拉斯·曹以買入評級啓動了對Eliem Therapeutics(納斯達克股票代碼:ELYM)的報道,並宣佈目標股價爲6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論